Complement inhibition does not impair the clinical antiviral capabilities of virus-specific T-cell therapy

The use of terminal complement blockade is compatible with virus-specific T-cell (VST) expansion and clinical effectiveness. VST and complement-blocking agent concurrent therapy may be safely used in patients with thrombotic microangiopathy and viral infections.

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Rubinstein, Jeremy D., Zhu, Xiang, Lutzko, Carolyn, Leemhuis, Tom, Cancelas, Jose A., Jodele, Sonata, Bollard, Catherine M., Hanley, Patrick J., Davies, Stella M., Grimley, Michael S., Nelson, Adam S.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2020
Assuntos:
Stimulus Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7391136/
https://ncbi.nlm.nih.gov/pubmed/32697816
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002252
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados